Catechin prodrugs and analogs: a new array of chemical entities with improved pharmacological and pharmacokinetic properties
Authors:
- 17 September 2013
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 30 (11) , 1438-1454
Abstract
Covering: 2001 to March 2013 Extensive research on tea catechins, mainly (–)-epigallocatechin gallate, has shown numerous health promoting effects. However, various clinical studies demonstrated several issues associated with tea catechins which account for their poor systemic bioavailability. In order to improve pharmacological activity and bioavailability of natural tea catechins, two major strategies have been adopted to date which include synthesizing catechin analogs/prodrugs and the development of novel drug delivery systems. In this review, we provide a detailed account of novel synthetic analogs/prodrugs as well as novel drug delivery approaches used for natural tea catechins to make them therapeutically potent drug-like molecules.Keywords
This publication has 142 references indexed in Scilit:
- Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancerProceedings of the National Academy of Sciences, 2012
- Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cellsBioorganic & Medicinal Chemistry, 2012
- Antitumor activity of novel fluoro-substituted (–)-epigallocatechin-3-gallate analogsCancer Letters, 2010
- Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogsBioorganic & Medicinal Chemistry, 2010
- Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green teaFood Research International, 2010
- Natural products in drug discoveryDrug Discovery Today, 2008
- The challenge of developing green tea polyphenols as therapeutic agentsInflammopharmacology, 2008
- Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitorInternational Journal of Cancer, 2008
- Synthesis of (2R,3R)-epigallocatechin-3-O-(4-hydroxybenzoate), a novel catechin from Cistus salvifolius, and evaluation of its proteasome inhibitory activitiesTetrahedron, 2007
- A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducerBioorganic & Medicinal Chemistry, 2007